Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

UPDATED: AstraZeneca, University of Manchester create new center for advanced drug delivery

The University of Manchester's North West Centre for Advanced Drug Delivery will study drug delivery topics in cancer and other diseases of interest to the  AstraZeneca,  in the latest example of the growing research collaboration between Big  Pharma  and academia.

Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs

A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.

GlaxoSmithKline cozies up to Five Prime for respiratory R&D

GlaxoSmithKline, facing widespread scrutiny for its underperforming respiratory business, has expanded its relationship with Five Prime Therapeutics, digging in to discover new treatments in the field.

Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will come too late

As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.

GSK taps Slaoui to chair flat-selling vaccines unit with an eye to the future

GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.

GlaxoSmithKline puts emerging markets chief Hussain in charge of global pharma ops

With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too.

Spinoff fervor grows: GSK looks at ViiV spinoff and investor tells Amgen to break things up

GlaxoSmithKline said today it is considering a spinoff of ViiV, the successful HIV-centric business it shares with Pfizer and Shionogi. Its talk of unlocking the "intrinsic" value of the business mirrored the language a hedge fund investor used hours earlier to suggest that Amgen do much the same thing, breaking into two companies, one for legacy drugs and one for new launches.

GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots

With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too.

Advair sales slide triggers another $1.6B in cost cuts at GlaxoSmithKline

Brace yourselves for layoffs at GlaxoSmithKline. The saga is familiar: An aging blockbuster loses steam to competing meds, and its maker gets out the cost-cutting ax to compensate. This time, the faltering drug is Advair, which adds some new twists to the story--including a warning to the whole pharma industry about formulary placement.

GlaxoSmithKline weighs an IPO for HIV-focused ViiV as it sharpens the budget ax

GlaxoSmithKline is considering taking its HIV joint venture public, tersely dropping hints of an IPO for ViiV Healthcare as it lays out plans to again slash R&D costs and refocus its business.